Trial Profile
A Phase 2 Study of OSI-906 in Patients With Asymptomatic or Mildly Symptomatic (Non-Opioid Requiring) Metastatic Castrate Resistant Prostate Cancer (CRPC)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Linsitinib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 23 Feb 2018 Status changed from active, no longer recruiting to discontinued ,according to the results published in the Investigational New Drugs
- 23 Feb 2018 Results published in the Investigational New Drugs
- 13 Jul 2012 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.